Currency, Actemra income boost Chugai's 3Q
This article was originally published in Scrip
Executive Summary
Top product Avastin (bevacizumab) continued to drive growth at Chugai in the nine months ended 30 September, when the firm's Japanese sales of the anti-VEGF antibody rose by a solid 17% to JPY53.7bn ($550m).